The licensing and distribution agreement expands the company’s injectable portfolio into the skin quality category.
Evolus has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo in the US.
Profhilo is an injectable treatment for skin quality currently available in more than 70 countries. Since its launch in 2015, more than 4.8 million treatments have been administered globally. The product uses a unique hyaluronic acid formulation for superficial application to improve skin hydration, elasticity, and smoothness.
Unlike traditional hyaluronic acid injectables designed primarily to restore volume, contour, or facial structure, Profhilo addresses a distinct patient need for refined aesthetic outcomes, according to a press release from Evolus. Evolus indicates that skin quality treatments represent a growth opportunity in the US and serve as a complementary segment to neurotoxin and dermal filler treatments.
“Profhilo represents an exciting new chapter for Evolus as we expand into skin quality, one of the fastest-growing and most innovative segments in injectable aesthetics,” says David Moatazedi, president and CEO of Evolus, in a release. “ … We believe skin quality represents the next frontier in injectable aesthetics in the United States, and with our established commercial infrastructure and digital platform, Evolus is uniquely positioned to help define and accelerate the growth of this emerging category while continuing to build the industry’s leading performance beauty company.”
The US injectable skin quality category is in its early stages compared to more developed international markets, according to the release from Evolus. In Europe, skin quality injectables have become a routine component of aesthetic treatment plans, which Evolus suggests highlights the long-term growth potential for the category in the US.
“We are pleased to partner with Evolus to bring Profhilo to the US,” says Salvatore Cincotti, general manager of IBSA, in a release. “Evolus has demonstrated a unique ability to build consumer-focused aesthetic brands and execute in the US market. We believe this collaboration creates a strong opportunity to expand access to Profhilo and establish the skin quality category with practitioners and patients in the world’s largest aesthetics market.”
Under the terms of the agreement, Evolus will be responsible for development activities required for US regulatory approval and will manage commercialization following approval. The agreement involves no upfront payments, and the economics are structured through a transfer-price model designed to support gross margins. Evolus indicates the agreement is not expected to impact its 2026 revenue, operating expense, or operating profit outlook.
